Good points. I recall reading in the Scheme booklet about...

Good points.

I recall reading in the Scheme booklet about broadly the outcome for the Viralytics employees. It's in the self-interest for the directors to have the Merck acquisition approved as they'll be working even closer with Merck. Who would turn down a professional chance of working with one of the biggest pharma companies in the world? Even with an attractive premium, I doubt it would incentivise the Board to move away from Merck. Even if BMS made a bid, I reckon the Board would still be hesitant. Keytruda is killing it in both the clinical and commercial space compared to BMS immunotherapy products.

I say this not out of spite but the Board will ultimately serve their own interests which makes sense. We still make a profit and they move onto getting cosy with Merck.